NCT04068194 2026-04-13
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
11 trialsNCT04172532 2026-04-13
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT06435260 2025-06-26
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT04106856 2025-04-06
SHAPER
University of Utah
Phase 1 Active not recruiting
NCT05370144 2024-11-18
A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
AHS Cancer Control Alberta
Phase NA Recruiting
NCT04636008 2024-08-06
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
West China Hospital
Phase 1/2 Recruiting
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT01936961 2017-06-27
I-CREST
Western Regional Medical Center
Phase NA Withdrawn